Therapy Areas: Cardiovascular
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
24 June 2025 - Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), a US-based specialty pharmaceutical company, on Monday announced the latest positive results from its Phase 2 FIGHT DMD trial evaluating i...
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
16 June 2025 - EDX Medical Group plc (AQSE: EDX), a developer of digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular disease and infectious diseases,...
Life Molecular Imaging's florbetaben (18F) granted orphan designation in Europe for Transthyretin (ATTR) Amyloidosis diagnosis
13 June 2025 - Germany-based Life Molecular Imaging GmbH (LMI) announced on Thursday that florbetaben (18F) has been granted orphan designation by the European Commission for the diagnosis of Transthy...
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
11 June 2025 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Wednesday an extension of its decade-long cardiovascular research collaboration with the Bro...
Niagen Bioscience reports positive results for nicotinamide riboside in rare genetic disorder Werner syndrome
9 June 2025 - Niagen Bioscience Inc (NASDAQ: NAGE) on Monday reported promising results from a peer-reviewed study demonstrating the potential of its patented nicotinamide riboside (NR) ingredient, Ni...
CirCode Biomed's IND application for HM2002 receives FDA clearance
2 June 2025 - Shanghai CirCode Biomed Co Ltd, a Chinese biotech company specialising in circular RNA therapies, announced on Friday that its leading pipeline HM2002 received Investigational New Drug (...